Goldline Pharmaceutical SME IPO Review
Goldline Pharmaceutical SME IPO has been reviewed by 1 analyst, and the overall consensus is May Apply — carrying a score of 60. Out of the 1 analysts who have covered this IPO, 0 recommend subscribing while 1 advises caution or avoidance — reflecting a mixed view from the analyst community.
The issue is priced in the band of ₹41-43 per share, with a minimum application size of 3000 shares (minimum investment of approximately ₹129,000 at the upper band). Subscription ran from 12 May 2026 to 14 May 2026. The issue size is ₹12 crore, entirely a fresh issue. As of now, the grey market premium (GMP) for Goldline Pharmaceutical SME IPO is quoting at ₹15 (35%), which gives a preliminary sense of how the street is pricing the listing — though GMP is unofficial and can swing sharply before the listing date. Scroll down for the full analyst breakdown and analyst-wise verdicts.
Researched & reviewed by
Abhishek Vohera,
Founder, IPO Guru
Last updated
Figures sourced from the RHP, BSE & NSE
Analyst verdict & score
One score out of 100, aggregated from every analyst verdict tracked for this issue. How it's calculated
Higher consensus indicates broader analyst agreement.
Detailed review
A written summary will appear here once enough analyst reports are in. Until then, read the analyst-wise verdicts below.
Analyst reviews
Ordered by each analyst's track record over the past year; analysts still building one are listed last.
| Analyst | Verdict | Report |
|---|---|---|
| May Apply |
Latest IPO reviews
How analysts rated the most recent mainboard issues — and, where they have listed, how the call played out.
Frequently asked
Should I apply for Goldline Pharmaceutical SME IPO?
The analyst consensus for Goldline Pharmaceutical SME IPO tracked on this page is May Apply, with a score of 60/100. Out of 1 analyst who have reviewed this IPO, 0 recommend subscribing. IPO Guru does not make buy or sell recommendations. Read the individual analyst reports and consult a SEBI-registered advisor before investing.
What does the score of 60 mean for Goldline Pharmaceutical SME IPO?
The score of 60 is an aggregate of all analyst ratings tracked for Goldline Pharmaceutical SME IPO. A score in this range reflects mixed views — some analysts are positive while others are cautious. Read the individual analyst verdicts above for more context.
What was the actual listing price of Goldline Pharmaceutical SME IPO?
Goldline Pharmaceutical SME IPO listed on May 19, 2026 at ₹59.75, against the issue price of ₹43 — a gain of +38.95% (₹16.75 per share). View the full GMP history page for day-wise pre-listing trends.
What is the price band and lot size of Goldline Pharmaceutical SME IPO?
Goldline Pharmaceutical SME IPO was priced at ₹41-43 per share. The minimum lot size is 3000 shares, making the minimum investment approximately ₹129,000 at the upper end of the price band. Subscription ran from 12 May 2026 to 14 May 2026.
Explore Goldline Pharmaceutical SME IPO further
Analyst views are one input. Read them alongside the demand, the grey market and the filings before you decide.
It has listed — go back to the fundamentals.
Live grey market premium, Kostak and Subject to Sauda, with the day-wise trend.
Category-wise demand from QIB, NII and retail investors, updated through the day.
Check with your PAN whether shares were credited to your demat account.
A verdict is an opinion, not a guarantee.
IPO Guru collects analyst views, GMP, subscription and allotment for every Mainboard and SME issue. Weigh them together — and against the offer document — before you apply.
Disclaimer: Grey Market Premium (GMP) is for information purposes and is not a guarantee of listing price. Always consult your financial advisor before investing.
